A Phase 4 interventional study of Rimegepant 75mg daily dosing and Rimegepant 75mg every other day dosing in Migraine, sponsored by Pfizer. Completed at 107 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-16.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.
Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 8th largest by enrollment, is one of 8 that started in 2022, is one of 9 in phase 4, and was the 13th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in United States, Israel
Ages 18+
Pfizer · Sites in India
Ages 18+
Pfizer · Sites in United States, Israel
Ages 18+
Medstar Health Research Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 16 · Phase 4 9
First in 2011; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,415 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 618 across the 32 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 8 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
47 studies in Migraine Disorders by Pfizer: 10 open now, 14 under way, 6 of them phase 3. Of 30 finished, 24 (80%) have results posted.
Among the 47 studies in Migraine Disorders by Pfizer, this one is the 11th largest by enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2022, is one of 6 in phase 4, and was the 24th registered.
Pfizer’s Migraine Disorders studies by the year they started, since 2007.
3 of the studies testing rimegepant in Migraine Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07918053Chinese PLA General HospitalA Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals | 2027-06 |
| NCT07667621University of South FloridaA Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing rimegepant in Migraine Disorders, from their registry updates:
Among Pfizer’s 47 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1) Target Population: Subject has at least 1 year history of episodic migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following:
Exclusion Criteria:
Sex and Reproductive Status:
Prohibited Medications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-blind Treatment Phase: Rimegepant 75 mg ODT dosed daily Open-Label Extension Phase: Rimegepant 75 mg ODT dosed daily
Drug: Rimegepant 75mg daily dosing
Double-blind Treatment Phase: Rimegepant 75 mg ODT every other day dosing alternating with matching placebo
Drug: Rimegepant 75mg every other day dosing
Double-blind Treatment Phase: matching placebo dosed daily
Drug: Placebo comparator dosing
Daily
Every other day
Placebo comparator
Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)
A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, and meeting either \>=2 of the pain features: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity OR \>=1 of the associated symptoms: nausea and/or vomiting; photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived for a month in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days through Month 3 \[Weeks 1 to 12\]/ (total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]). Mean change in number of migraine days per month in DBT phase as compared to OP phase was calculated and reported in this outcome measure.
Time frame: Observation phase (from 31 days prior to randomization), DBT phase (through Month 3 [Week 1 to 12])
Percentage of Participants With Greater Than Equal to (>=) 50 Percent (%) Reduction From OP in Number of Moderate to Severe Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)
Percentage of participants with \>= 50% reduction from OP, in number of migraine days (moderate or severe) in the overall DBT phase is reported in this outcome measure. The number of migraine days per month were prorated to 28 days and derived for a month in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days through Month 3 \[Weeks 1 to 12\]/ (total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]).
Time frame: DBT phase (through Month 3 [Week 1 to 12])
Mean Change From OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of DBT Phase
A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, and meeting either \>=2 of the pain features: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity OR \>=1 of the associated symptoms: nausea and/or vomiting; photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived a month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in the month) / (total number of e-diary efficacy data in the month). Mean change in number of migraine days per month in the last 4 weeks of DBT phase as compared to OP phase was calculated and reported in this outcome measure.
Time frame: Observation phase (from 31 days before randomization), Week 9 to Week 12 of the DBT phase
Mean Change From OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of DBT Phase
A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, and meeting either \>=2 of the pain features: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity OR \>=1 of the associated symptoms: nausea and/or vomiting; photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived a month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in the month / (total number of e-diary efficacy data in the month. Mean change in number of migraine days per month in the first 4 weeks of DBT phase as compared to OP phase was calculated and reported in this outcome measure.
Time frame: Observation phase (from 31 days before randomization), Week 1 to Week 4 of the DBT phase
Mean Number of Acute Migraine-Specific Medication Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)
An acute migraine-specific medication day was defined as any calendar day during which the participant took a migraine-specific medication (i.e., triptan or ergotamine). The number of acute migraine-specific medication days per month were prorated to 28 days and derived for on-DBT efficacy analysis period as follows: 28\*(total number of acute migraine-specific medication days through Month 3/ (total number of e-Diary efficacy data days through Month 3).
Time frame: DBT phase (through Month 3 [Week 1 to 12])
Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) Version 2.1 Restrictive Role Function Domain Score at Week 12 of the DBT Phase
MSQoL is a self-administered, 14-item instrument validated in 3 domains: role restriction, role prevention, and the emotional function. The restrictive role function domain consisted of 7 items that described how migraine limited one's daily social and work-related activities. Participants were required to respond to items using a 6-point scale ranging from 1 to 6, where "1: none of the time," "2: a little bit of the time," "3: some of the time," "4: a good bit of the time," "5: most of the time," and "6: all of the time,". Item scores were recoded using (7 - original score). Raw dimension scores for restrictive role function domain were computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that lower score (0) indicated poor quality of life and higher scores (100) indicated better quality of life.
Time frame: Baseline (Day 1), Week 12 of the DBT phase
Number of Participants With Mild, Moderate and Severe Adverse Events (AEs) in DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were categorized as mild: usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate: was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but posed no significant or permanent risk of harm to the participant. Severe: Interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. AEs included both non-SAEs and serious adverse events (SAEs).
Time frame: DBT: From Week 1 to Week 20
Number of Participants With Mild, Moderate and Severe AEs OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were categorized as mild: usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate: was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but posed no significant or permanent risk of harm to the participant. Severe: Interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. AEs included both non-SAEs and SAEs.
Time frame: OLE: From Week 12 to Week 32
Number of Participants With Serious Adverse Events (SAEs) in DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was any event that met any of the following criteria at any dose: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of the participant who received rimegepant and other important medical events.
Time frame: DBT: From Week 1 to Week 20
Number of Participants With SAEs in OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was any event that met any of the following criteria at any dose: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of the participant who received rimegepant and other important medical events.
Time frame: OLE: From Week 12 to Week 32
Number of Participants With AEs Leading to Study Drug Discontinuation in DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with adverse events leading to study drug discontinuation were reported.
Time frame: DBT: From Week 1 to Week 12
Number of Participants With AEs Leading to Study Drug Discontinuation in OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with adverse events leading to study drug discontinuation were reported.
Time frame: OLE: From Week 12 to Week 24
Number of Participants With Grade 3 to 4 Laboratory Abnormalities in DBT Phase
The laboratory parameters were graded according to the National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) version 5.0 and using division of AIDS (DAIDS) toxicity grading scale version 2.1 (glucose, low density lipoprotein \[LDL\] cholesterol, uric acid and urinalysis) and for other parameters (eosinophils, hemoglobin, leukocytes, albumin, lymphocytes, neutrophils, platelets, alanine aminotransferase, alkaline phosphatase ,aspartate aminotransferase, bicarbonate, bilirubin, calcium, cholesterol, creatine kinase, creatinine, lactate dehydrogenase, potassium, sodium, triglycerides) CTCAE version v5.0 was used. Severity were graded as Grade 1=mild AE, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening consequences; urgent intervention indicated. Number of participants according to Grade 3 or 4 laboratory abnormalities are reported. Only laboratory abnormalities with non-zero values in any of the treatment arms are reported.
Time frame: DBT: From Week 1 to Week 20
Number of Participants With Grade 3 to 4 Laboratory Abnormalities in OLE Phase
The laboratory parameters were graded according to the NCI CTCAE version 5.0 and using DAIDS toxicity grading scale version 2.1 (glucose, LDL cholesterol, uric acid and urinalysis). And for other parameters (eosinophils, hemoglobin, leukocytes, albumin, lymphocytes, neutrophils, platelets, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, cholesterol, creatine kinase, creatinine, lactate dehydrogenase, potassium, sodium, triglycerides) CTCAE version v5.0 was used. Severity was graded as Grade 1=mild AE, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening consequences; urgent intervention indicated. Number of participants according to Grade 3 or 4 laboratory abnormalities are reported. Only laboratory abnormalities with non-zero values in any of the treatment arms are reported.
Time frame: OLE: From Week 12 to Week 32
Number of Participants With Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) Elevations > 3* Upper Limit of Normal (ULN) Concurrent With (Total Bilirubin) TBL >2*ULN in DBT Phase
Number of participants with AST or ALT \>3\*ULN concurrent with TBL \>2\*ULN in DBT phase were reported in this outcome measure.
Time frame: DBT: From Week 1 to Week 20
Number of Participants With AST or ALT Elevations > 3* ULN Concurrent With TBL >2*ULN in OLE Phase
Number of participants with AST or ALT \>3\*ULN concurrent with TBL \>2\*ULN in DBT phase were reported in this outcome measure.
Time frame: OLE: From Week 12 to Week 32
Number of Participants With Hepatic-Related AEs in the DBT Phase
\\An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic-related AEs included: alanine aminotransferase and aspartate aminotransferase increased, liver function test abnormal, liver function test increased, bilirubin conjugated increased, blood bilirubin increased, transaminases increased and hyperbilirubinemia. Number of participants with any hepatic-related AEs in the DBT phase were reported in this outcome measure.
Time frame: DBT: From Week 1 to Week 20
Number of Participants With Hepatic-Related AEs in the OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic AEs included: alanine aminotransferase and aspartate aminotransferase increased, liver function test abnormal, bilirubin conjugated, hepatic enzyme increased, blood bilirubin unconjugated increased, blood bilirubin and transaminases increased and hepatic function abnormal. Number of participants with any hepatic-related AEs in the OLE phase were reported in this outcome measure.
Time frame: OLE: From Week 12 to Week 32
Number of Participants With Hepatic-Related AEs Leading to Study Drug Discontinuation in the DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic-related AEs included: alanine aminotransferase and aspartate aminotransferase increased, liver function test and blood bilirubin increased. Number of participants with any hepatic-related AEs leading to study drug discontinuation is reported in this outcome measure.
Time frame: DBT: From Week 1 to Week 12
Number of Participants With Hepatic-Related AEs Leading to Study Drug Discontinuation in the OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic-related AEs included: aspartate aminotransferase increased and liver function test abnormal. Number of participants with any hepatic-related AEs leading to study drug discontinuation is reported in this outcome measure.
Time frame: OLE: From Week 12 to Week 24
| Milestone | Double Blind (DB) Rimegepant/ Placebo/ Open Label (OL) Rimegepant | DB Rimegepant/OL Rimegepant | DB Placebo/OL Rimegepant |
|---|---|---|---|
| Started | 234 | 232 | 233 |
| Treated | 232 | 229 | 231 |
| Completed | 204 | 209 | 208 |
| Not completed | 30 | 23 | 25 |
| Withdrew: Adverse event | 7 | 2 | 5 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 |
| Withdrew: Non-compliance | 1 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 2 | 1 |
| Withdrew: Protocol-specified withdrawal criterion met | 4 | 6 | 5 |
| Withdrew: Withdrawal of consent | 8 | 5 | 7 |
| Withdrew: Other | 7 | 3 | 4 |
| Withdrew: Randomized, not treated | 2 | 3 | 2 |
| Milestone | Double Blind (DB) Rimegepant/ Placebo/ Open Label (OL) Rimegepant | DB Rimegepant/OL Rimegepant | DB Placebo/OL Rimegepant |
|---|---|---|---|
| Started | 182 | 196 | 195 |
| Completed | 170 | 187 | 183 |
| Not completed | 12 | 9 | 12 |
| Withdrew: Adverse event | 4 | 1 | 1 |
| Withdrew: Extension phase eligibility failure | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 |
| Withdrew: Non-compliance | 0 | 0 | 1 |
| Withdrew: Other | 3 | 5 | 4 |
| Withdrew: Withdrawal of consent | 3 | 1 | 5 |
A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, and meeting either \>=2 of the pain features: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity OR \>=1 of the associated symptoms: nausea and/or vomiting; photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived for a month in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days through Month 3 \[Weeks 1 to 12\]/ (total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]). Mean change in number of migraine days per month in DBT phase as compared to OP phase was calculated and reported in this outcome measure.
| Days per month | DB Rimegepant/ Placebo | DB Rimegepant | DB Placebo |
|---|---|---|---|
| Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12) | -2.9 (-3.31 to -2.42) | -4.0 (-4.44 to -3.60) | -2.2 (-2.65 to -1.85) |
Percentage of participants with \>= 50% reduction from OP, in number of migraine days (moderate or severe) in the overall DBT phase is reported in this outcome measure. The number of migraine days per month were prorated to 28 days and derived for a month in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days through Month 3 \[Weeks 1 to 12\]/ (total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]).
| Percentage of participants | DB Rimegepant/ Placebo | DB Rimegepant | DB Placebo |
|---|---|---|---|
| Percentage of Participants With Greater Than Equal to (>=) 50 Percent (%) Reduction From OP in Number of Moderate to Severe Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) | 40.5 (33.5 to 47.9) | 58.1 (50.7 to 65.3) | 33.3 (26.4 to 40.2) |
A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, and meeting either \>=2 of the pain features: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity OR \>=1 of the associated symptoms: nausea and/or vomiting; photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived a month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in the month) / (total number of e-diary efficacy data in the month). Mean change in number of migraine days per month in the last 4 weeks of DBT phase as compared to OP phase was calculated and reported in this outcome measure.
| Days per month | DB Rimegepant/ Placebo | DB Rimegepant | DB Placebo |
|---|---|---|---|
| Mean Change From OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of DBT Phase | -3.0 (-3.59 to -2.49) | -4.2 (-4.75 to -3.75) | -2.8 (-3.33 to -2.33) |
A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, and meeting either \>=2 of the pain features: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity OR \>=1 of the associated symptoms: nausea and/or vomiting; photophobia and phonophobia. The number of migraine days per month were prorated to 28 days and derived a month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in the month / (total number of e-diary efficacy data in the month. Mean change in number of migraine days per month in the first 4 weeks of DBT phase as compared to OP phase was calculated and reported in this outcome measure.
| Days per month | DB Rimegepant/ Placebo | DB Rimegepant | DB Placebo |
|---|---|---|---|
| Mean Change From OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of DBT Phase | -2.7 (-3.17 to -2.16) | -3.6 (-4.10 to -3.16) | -1.5 (-1.97 to -1.05) |
An acute migraine-specific medication day was defined as any calendar day during which the participant took a migraine-specific medication (i.e., triptan or ergotamine). The number of acute migraine-specific medication days per month were prorated to 28 days and derived for on-DBT efficacy analysis period as follows: 28\*(total number of acute migraine-specific medication days through Month 3/ (total number of e-Diary efficacy data days through Month 3).
| Days per month | DB Rimegepant/ Placebo | DB Rimegepant | DB Placebo |
|---|---|---|---|
| Mean Number of Acute Migraine-Specific Medication Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) | 2.3 (1.87 to 2.82) | 1.5 (1.13 to 1.88) | 2.8 (2.28 to 3.35) |
MSQoL is a self-administered, 14-item instrument validated in 3 domains: role restriction, role prevention, and the emotional function. The restrictive role function domain consisted of 7 items that described how migraine limited one's daily social and work-related activities. Participants were required to respond to items using a 6-point scale ranging from 1 to 6, where "1: none of the time," "2: a little bit of the time," "3: some of the time," "4: a good bit of the time," "5: most of the time," and "6: all of the time,". Item scores were recoded using (7 - original score). Raw dimension scores for restrictive role function domain were computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that lower score (0) indicated poor quality of life and higher scores (100) indicated better quality of life.
| Units on a scale | DB Rimegepant/ Placebo | DB Rimegepant | DB Placebo |
|---|---|---|---|
| Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) Version 2.1 Restrictive Role Function Domain Score at Week 12 of the DBT Phase | 21.3 (18.37 to 24.33) | 29.1 (25.79 to 32.31) | 18.9 (15.91 to 21.97) |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were categorized as mild: usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate: was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but posed no significant or permanent risk of harm to the participant. Severe: Interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. AEs included both non-SAEs and serious adverse events (SAEs).
| Participants | DB Rimegepant/ Placebo | DB Rimegepant | DB Placebo |
|---|---|---|---|
| Mild | 73 | 86 | 91 |
| Moderate | 42 | 22 | 43 |
| Severe | 4 | 3 | 2 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were categorized as mild: usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate: was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but posed no significant or permanent risk of harm to the participant. Severe: Interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. AEs included both non-SAEs and SAEs.
| Participants | DB RMG EOD/DB PBO EOD/ OL RMG QD | DB RMG QD/ OL RMG QD | DB PBO QD/ OL RMG QD |
|---|---|---|---|
| Mild | 65 | 57 | 65 |
| Moderate | 30 | 22 | 25 |
| Severe | 2 | 2 | 1 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was any event that met any of the following criteria at any dose: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of the participant who received rimegepant and other important medical events.
| Participants | DB Rimegepant/ Placebo | DB Rimegepant | DB Placebo |
|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) in DBT Phase | 3 | 2 | 1 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was any event that met any of the following criteria at any dose: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of the participant who received rimegepant and other important medical events.
| Participants | DB RMG EOD/DB PBO EOD/ OL RMG QD | DB RMG QD/ OL RMG QD | DB PBO QD/ OL RMG QD |
|---|---|---|---|
| Number of Participants With SAEs in OLE Phase | 2 | 2 | 2 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with adverse events leading to study drug discontinuation were reported.
| Participants | DB Rimegepant/ Placebo | DB Rimegepant | DB Placebo |
|---|---|---|---|
| Number of Participants With AEs Leading to Study Drug Discontinuation in DBT Phase | 6 | 1 | 4 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with adverse events leading to study drug discontinuation were reported.
| Participants | DB RMG EOD/DB PBO EOD/ OL RMG QD | DB RMG QD/ OL RMG QD | DB PBO QD/ OL RMG QD |
|---|---|---|---|
| Number of Participants With AEs Leading to Study Drug Discontinuation in OLE Phase | 4 | 1 | 1 |
The laboratory parameters were graded according to the National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) version 5.0 and using division of AIDS (DAIDS) toxicity grading scale version 2.1 (glucose, low density lipoprotein \[LDL\] cholesterol, uric acid and urinalysis) and for other parameters (eosinophils, hemoglobin, leukocytes, albumin, lymphocytes, neutrophils, platelets, alanine aminotransferase, alkaline phosphatase ,aspartate aminotransferase, bicarbonate, bilirubin, calcium, cholesterol, creatine kinase, creatinine, lactate dehydrogenase, potassium, sodium, triglycerides) CTCAE version v5.0 was used. Severity were graded as Grade 1=mild AE, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening consequences; urgent intervention indicated. Number of participants according to Grade 3 or 4 laboratory abnormalities are reported. Only laboratory abnormalities with non-zero values in any of the treatment arms are reported.
| Participants | DB Rimegepant/ Placebo | DB Rimegepant | DB Placebo |
|---|---|---|---|
| Lymphocytes, low | 0 | 0 | 1 |
| Alanine Aminotransferase | 0 | 1 | 1 |
| Aspartate Aminotransferase | 0 | 0 | 1 |
| Creatine Kinase | 2 | 1 | 4 |
| Glucose, low | 0 | 1 | 0 |
| LDL Cholesterol | 6 | 4 | 9 |
| LDL Cholesterol, fasting | 4 | 3 | 3 |
| LDL Cholesterol, not fasting | 2 | 1 | 6 |
| Sodium, high | 0 | 0 | 1 |
| Triglycerides | 0 | 1 | 0 |
| Triglycerides, fasting | 0 | 1 | 0 |
| Urinalysis Glucose | 0 | 1 | 0 |
The laboratory parameters were graded according to the NCI CTCAE version 5.0 and using DAIDS toxicity grading scale version 2.1 (glucose, LDL cholesterol, uric acid and urinalysis). And for other parameters (eosinophils, hemoglobin, leukocytes, albumin, lymphocytes, neutrophils, platelets, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, cholesterol, creatine kinase, creatinine, lactate dehydrogenase, potassium, sodium, triglycerides) CTCAE version v5.0 was used. Severity was graded as Grade 1=mild AE, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening consequences; urgent intervention indicated. Number of participants according to Grade 3 or 4 laboratory abnormalities are reported. Only laboratory abnormalities with non-zero values in any of the treatment arms are reported.
| Participants | DB RMG EOD/DB PBO EOD/ OL RMG QD | DB RMG QD/ OL RMG QD | DB PBO QD/ OL RMG QD |
|---|---|---|---|
| Alanine Aminotransferase | 1 | 1 | 1 |
| Aspartate Aminotransferase | 0 | 1 | 0 |
| Creatine Kinase | 3 | 0 | 5 |
| LDL Cholesterol | 7 | 8 | 4 |
| LDL Cholesterol, fasting | 4 | 4 | 0 |
| LDL Cholesterol, not fasting | 3 | 4 | 4 |
| Potassium, low | 0 | 1 | 0 |
| Potassium, high | 1 | 0 | 1 |
| Triglycerides | 0 | 1 | 0 |
| Triglycerides, not fasting | 0 | 1 | 0 |
| Urinalysis Glucose | 1 | 1 | 0 |
Number of participants with AST or ALT \>3\*ULN concurrent with TBL \>2\*ULN in DBT phase were reported in this outcome measure.
| Participants | DB Rimegepant/ Placebo | DB Rimegepant | DB Placebo |
|---|---|---|---|
| Number of Participants With Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) Elevations > 3* Upper Limit of Normal (ULN) Concurrent With (Total Bilirubin) TBL >2*ULN in DBT Phase | 0 | 0 | 0 |
Number of participants with AST or ALT \>3\*ULN concurrent with TBL \>2\*ULN in DBT phase were reported in this outcome measure.
| Participants | DB RMG EOD/DB PBO EOD/ OL RMG QD | DB RMG QD/ OL RMG QD | DB PBO QD/ OL RMG QD |
|---|---|---|---|
| Number of Participants With AST or ALT Elevations > 3* ULN Concurrent With TBL >2*ULN in OLE Phase | 0 | 0 | 0 |
\\An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic-related AEs included: alanine aminotransferase and aspartate aminotransferase increased, liver function test abnormal, liver function test increased, bilirubin conjugated increased, blood bilirubin increased, transaminases increased and hyperbilirubinemia. Number of participants with any hepatic-related AEs in the DBT phase were reported in this outcome measure.
| Participants | DB Rimegepant/ Placebo | DB Rimegepant | DB Placebo |
|---|---|---|---|
| Number of Participants With Hepatic-Related AEs in the DBT Phase | 7 | 8 | 8 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic AEs included: alanine aminotransferase and aspartate aminotransferase increased, liver function test abnormal, bilirubin conjugated, hepatic enzyme increased, blood bilirubin unconjugated increased, blood bilirubin and transaminases increased and hepatic function abnormal. Number of participants with any hepatic-related AEs in the OLE phase were reported in this outcome measure.
| Participants | DB RMG EOD/DB PBO EOD/ OL RMG QD | DB RMG QD/ OL RMG QD | DB PBO QD/ OL RMG QD |
|---|---|---|---|
| Number of Participants With Hepatic-Related AEs in the OLE Phase | 11 | 4 | 6 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic-related AEs included: alanine aminotransferase and aspartate aminotransferase increased, liver function test and blood bilirubin increased. Number of participants with any hepatic-related AEs leading to study drug discontinuation is reported in this outcome measure.
| Participants | DB Rimegepant/ Placebo | DB Rimegepant | DB Placebo |
|---|---|---|---|
| Number of Participants With Hepatic-Related AEs Leading to Study Drug Discontinuation in the DBT Phase | 4 | 1 | 2 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. Hepatic-related AEs included: aspartate aminotransferase increased and liver function test abnormal. Number of participants with any hepatic-related AEs leading to study drug discontinuation is reported in this outcome measure.
| Participants | DB RMG EOD/DB PBO EOD/ OL RMG QD | DB RMG QD/ OL RMG QD | DB PBO QD/ OL RMG QD |
|---|---|---|---|
| Number of Participants With Hepatic-Related AEs Leading to Study Drug Discontinuation in the OLE Phase | 1 | 1 | 1 |
Collected over Baseline up to 8 weeks after last dose of study drug (DBT phase: Week 1 to Week 20; OLE phase Week 12 to Week 32). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Rimegepant/ Placebo | 0/232 (0%) | 3/232 (1.3%) | 13/232 (5.6%) |
| DB Rimegepant | 0/229 (0%) | 2/229 (0.9%) | 13/229 (5.7%) |
| DB Placebo | 0/231 (0%) | 1/231 (0.4%) | 13/231 (5.6%) |
| DB RMG EOD/DB PBO EOD/ OL RMG QD | 0/182 (0%) | 2/182 (1.1%) | 17/182 (9.3%) |
| DB RMG QD/ OL RMG QD | 0/196 (0%) | 2/196 (1%) | 19/196 (9.7%) |
| DB PBO QD/ OL RMG QD | 0/195 (0%) | 2/195 (1%) | 13/195 (6.7%) |
| Event | DB Rimegepant/ Placebo | DB Rimegepant | DB Placebo | DB RMG EOD/DB PBO EOD/ OL RMG QD | DB RMG QD/ OL RMG QD | DB PBO QD/ OL RMG QD |
|---|---|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 0/232 | 0/229 | 0/231 | 1/182 | 0/196 | 0/195 |
| Status migrainosusNervous system disorders | 1/232 | 0/229 | 0/231 | 1/182 | 0/196 | 0/195 |
| AppendicitisInfections and infestations | 0/232 | 0/229 | 0/231 | 0/182 | 0/196 | 1/195 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/232 | 0/229 | 0/231 | 0/182 | 0/196 | 1/195 |
| Liver function test abnormalInvestigations | 0/232 | 0/229 | 0/231 | 0/182 | 1/196 | 0/195 |
| CostochondritisMusculoskeletal and connective tissue disorders | 0/232 | 0/229 | 0/231 | 0/182 | 1/196 | 0/195 |
| Infected cystInfections and infestations | 0/232 | 1/229 | 0/231 | 0/182 | 0/196 | 0/195 |
| Urinary tract infectionInfections and infestations | 0/232 | 1/229 | 0/231 | 0/182 | 0/196 | 0/195 |
| PneumoniaInfections and infestations | 0/232 | 0/229 | 1/231 | 0/182 | 0/196 | 0/195 |
| Crohn's diseaseGastrointestinal disorders | 1/232 | 0/229 | 0/231 | 0/182 | 0/196 | 0/195 |
| Event | DB Rimegepant/ Placebo | DB Rimegepant | DB Placebo | DB RMG EOD/DB PBO EOD/ OL RMG QD | DB RMG QD/ OL RMG QD | DB PBO QD/ OL RMG QD |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 13/232 | 13/229 | 13/231 | 13/182 | 5/196 | 7/195 |
| COVID-19Infections and infestations | 0/232 | 0/229 | 0/231 | 4/182 | 14/196 | 6/195 |
Double-blind treatment safety population included participants in the enrolled analysis set who took greater than equal to (\>=) 1 dose of double-blind study drug (rimegepant or placebo).
| Age, Continuous(Years) | DB Rimegepant/ Placebo/ OL Rimegepant | DB Rimegepant/OL Rimegepant | DB Placebo/OL Rimegepant | Total |
|---|---|---|---|---|
| Mean | 42.0 ± 11.96 | 43.9 ± 12.05 | 42.9 ± 12.35 | 43 ± 12.13 |
| Sex: Female, Male(Participants) | DB Rimegepant/ Placebo/ OL Rimegepant | DB Rimegepant/OL Rimegepant | DB Placebo/OL Rimegepant | Total |
|---|---|---|---|---|
| Female | 201 | 192 | 207 | 600 |
| Male | 31 | 37 | 24 | 92 |
| Ethnicity (NIH/OMB)(Participants) | DB Rimegepant/ Placebo/ OL Rimegepant | DB Rimegepant/OL Rimegepant | DB Placebo/OL Rimegepant | Total |
|---|---|---|---|---|
| Hispanic or Latino | 23 | 20 | 25 | 68 |
| Not Hispanic or Latino | 47 | 50 | 51 | 148 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | DB Rimegepant/ Placebo/ OL Rimegepant | DB Rimegepant/OL Rimegepant | DB Placebo/OL Rimegepant | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 5 | 1 | 6 | 12 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 2 |
| Black or African American | 6 | 12 | 6 | 24 |
| White | 56 | 56 | 63 | 175 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
Showing the first 100 of 107 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2022 to primary completion in Oct 2024, 31 months.
Results were first posted in Dec 2025, 1 year 1 month after primary completion.
Of 28 industry-sponsored phase 4 interventional studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 31 months is above that.
Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimegepant